- Trial phase
- Approved
- Time to market
- Already on the market, MONOVISC is an approved, commercialized single-injection viscosupplement sold within Anika's Commercial Channel (no pending approval for this product).
- Why 3/10
- MONOVISC is an already-approved, marketed product with no hard, dated binary catalyst of its own in the next ~12 months, the company's upcoming regulatory catalysts (Cingal NDA submission, Hyalofast PMA decision) belong to other assets, so per the rubric an approved drug with no pending decision caps at 3-5; with MONOVISC being one of several products in a ~$200M company, it scores 3.
MONOVISC is not the near-term trade for ANIK, it is the baseline commercial cash generator, so watch quarterly "Commercial Channel" revenue and gross-margin trends as the read-through on the OA franchise. The share-price drivers to track instead are the dated catalysts on other Anika assets: the Cingal NDA submission timeline and Hyalofast PMA updates (Hyalofast was removed from 2027 revenue guidance due to FDA timing uncertainty). Note the stock is extended (+138% over 12 months, RSI-14 ~78.7, forward P/E ~47), so upside is partially priced in.
Price Chart
Executive Summary
MONOVISC is Anika Therapeutics' approved single-injection hyaluronic-acid viscosupplement for knee osteoarthritis, part of Anika's osteoarthritis pain-management franchise (with multi-injection ORTHOVISC and pipeline product CINGAL). It is a mature commercial product with no pending regulatory decision of its own: Q2 2026 results showed the broader franchise driving record Commercial Channel revenue of $13.9M (+17% YoY) within a $32.6M total-revenue quarter that beat consensus, with raised FY2026 guidance. The stock has run +138% over 12 months (price ~$19.28, near its 52-week high), but the actual binary catalysts are other assets (Cingal NDA, Hyalofast PMA), making MONOVISC a steady cash-flow contributor rather than a near-term catalyst.
How It Works
MONOVISC is a single injection of a thick, gel-like hyaluronic acid (a natural lubricating molecule found in joint fluid) into the knee. It restores the cushioning and viscosity of the joint fluid ("viscosupplementation") to relieve pain from knee osteoarthritis, a mechanical lubrication treatment, not a drug that changes disease course.
Trial Status
No active Phase 2/3 registrational trial is tracked for MONOVISC in local databases, it is a marketed product generating revenue (Anika's Q2 2026 filing analysis lists MONOVISC among the company's commercial drug names, alongside ORTHOVISC, CINGAL, HYALOFAST and INTEGRITY). Anika's pending regulatory work (Cingal NDA, Hyalofast PMA) is on separate pipeline assets.
The Two-Sided Case
Upcoming Catalysts
- Cingal NDA submission, company guided to submission upon completion of two required studies (bioequivalence study initiation on track; Q3 earnings call is the venue for timeline updates)
- Hyalofast PMA decision/timing, FDA deficiency-letter resolution; removed from 2027 revenue guidance, creating binary risk
- Quarterly earnings (Q3 2026), Commercial Channel revenue and gross-margin read-through for the MONOVISC/ORTHOVISC franchise
- Barrington Research and B. Riley Securities maintain Buy/Outperform ratings; watch for price-target revisions after the guidance raise
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Anika Therapeutics, Inc. 8-K ANIK ·Originating report